Prediction: These Dividend Stocks Could Outperform Growth Stocks in the Next Decade

The article identifies AbbVie and Apple as strong dividend-paying stocks poised for long-term outperformance. AbbVie has successfully navigated its Humira patent cliff, with immunology drugs Skyrizi and Rinvoq driving future revenue growth and Rinvoq's patent secured until 2037, supporting its 53-year dividend growth history. Apple, transitioning from a pure growth stock, is leveraging its vast ecosystem and expanding high-margin services segment to enhance profitability and has ample capacity for continued dividend increases, while also addressing tariff challenges through localized manufacturing.

Analysis

AbbVie (ABBV) and Apple (AAPL) are presented as robust dividend-paying companies poised for long-term outperformance against growth-oriented counterparts. Both firms demonstrate strong capital allocation strategies, with AbbVie boasting a 53-year dividend growth streak and Apple having doubled its dividend over the past decade. This suggests a focus on shareholder returns alongside strategic business development.

AbbVie has successfully navigated the significant patent cliff of Humira, with immunology drugs Skyrizi and Rinvoq now driving future revenue and earnings growth. Rinvoq's patent exclusivity has been secured until at least 2037 in the U.S., providing a clear runway for these therapies. The company's forward dividend yield of 2.8% and a reasonable cash payout ratio of 61.8% underscore its capacity for sustained dividend increases and diversified revenue streams.

Apple, while no longer solely a "growth stock," leverages its vast ecosystem of over 2 billion devices and a rapidly expanding services segment, which now exceeds 1 billion paid subscriptions. This high-margin services unit is expected to enhance overall profitability and margins. Furthermore, Apple's low cash payout ratio of 14% indicates substantial room for continued dividend hikes, complementing its strategy to mitigate tariff impacts through localized manufacturing.

Key Decisions for Investors

• Investors should consider AbbVie for its defensive qualities, secure patent runway for key growth drivers like Rinvoq until 2037, and consistent dividend growth potential.
• For Apple, focus on its expanding high-margin services segment and vast ecosystem as primary drivers for future profitability and dividend increases, rather than solely on traditional revenue growth.
• Monitor the sales trajectory of AbbVie's immunology drugs and Apple's services subscription growth as critical indicators for sustained long-term outperformance.